Last verified · v1.0

Calculator · health

Has Bled Bleeding Risk Score Calculator

The HAS-BLED calculator estimates annual major bleeding risk in AF patients by scoring 9 clinical risk factors to guide anticoagulation decisions.

FreeInstantNo signupOpen source

Inputs

Hypertension (uncontrolled, SBP >160 mmHg)

Abnormal Renal Function

Abnormal Liver Function

Prior Stroke History

Prior Major Bleeding or Predisposition

Labile INR (unstable/high INRs, TTR <60%)

Patient Age

Medication Usage Predisposing to Bleeding

Alcohol Usage (≥8 drinks/week)

HAS-BLED Score

—

Get a plain-English breakdown of your result with practical next steps.

HAS-BLED Score—points

The formula

How the
result is
computed.

What Is the HAS-BLED Score?

The HAS-BLED score is a validated clinical prediction tool designed to estimate the 1-year risk of major bleeding in patients with atrial fibrillation (AF) who are candidates for anticoagulation therapy. Developed by Pisters et al. and validated against the Euro Heart Survey dataset of 3,978 AF patients, the score enables clinicians to weigh stroke prevention benefits against serious hemorrhagic risk. The acronym stands for Hypertension, Abnormal renal/liver function, Stroke history, Bleeding history or predisposition, Labile INR, Elderly age, and Drugs/alcohol use.

HAS-BLED Formula

The total score equals the sum of all applicable risk-factor points:

HAS-BLED = H + A + S + B + L + E + D_drugs + D_alcohol

The maximum possible score is 9 points. The A component (renal plus liver dysfunction) and the D component (drugs plus alcohol) can each contribute up to 2 points; all remaining variables contribute 1 point each.

Variable Definitions and Point Values

H — Hypertension (1 point): Uncontrolled systolic blood pressure greater than 160 mmHg. Adequately treated hypertension does not score a point.
A — Abnormal Renal or Liver Function (1–2 points): Renal dysfunction is defined as dialysis dependence, renal transplant, or serum creatinine above 2.26 mg/dL (200 µmol/L), scoring 1 point. Liver dysfunction — including cirrhosis, bilirubin more than twice the upper limit of normal, or AST/ALT/alkaline phosphatase more than three times normal — scores 1 additional point independently.
S — Stroke History (1 point): Any prior ischemic or hemorrhagic stroke.
B — Bleeding History or Predisposition (1 point): Previous major bleeding episode, anemia, or a diagnosed condition that increases bleeding susceptibility.
L — Labile INR (1 point): Unstable international normalized ratio, or time in therapeutic range (TTR) below 60% on warfarin therapy.
E — Elderly Age (1 point): Patient age greater than 65 years.
D — Drugs or Alcohol (1–2 points): Concomitant antiplatelet agents or NSAIDs score 1 point. Alcohol consumption of 8 or more drinks per week scores an additional 1 point independently.

Score Interpretation

According to the NIH/PMC comparative analysis of online bleeding risk calculators, the HAS-BLED score stratifies annual major bleeding risk as follows:

Score 0–1: Low risk — estimated annual major bleeding rate approximately 1.0–1.1%
Score 2: Moderate risk — estimated annual major bleeding rate approximately 1.9%
Score 3: High risk — estimated annual major bleeding rate approximately 3.7%; clinical review of modifiable factors is warranted
Score 4–5+: Very high risk — annual rates of 8.7% and 12.5% respectively; aggressive factor modification required before initiating or continuing anticoagulation

A score of 3 or greater does not automatically contraindicate anticoagulation. Rather, it signals that modifiable risk factors — uncontrolled hypertension, concurrent NSAID use, labile INR, or excessive alcohol — should be corrected proactively.

Clinical Use and Context

The HAS-BLED score is endorsed by the European Society of Cardiology (ESC) AF management guidelines. Clinicians use it alongside the CHA₂DS₂-VASc thromboembolic risk score to perform a net clinical benefit analysis. Research from the Harvard DASH anticoagulation optimization study confirms that elevated HAS-BLED scores should prompt risk-factor reduction rather than blanket anticoagulation avoidance, since stroke risk in AF frequently exceeds bleeding risk — particularly at CHA₂DS₂-VASc scores of 2 or higher.

Worked Example

Consider a 72-year-old patient with uncontrolled hypertension (SBP 168 mmHg), a prior ischemic stroke, serum creatinine of 2.5 mg/dL, and regular ibuprofen use:

H (hypertension, SBP 168 mmHg): 1 point
A (renal dysfunction, creatinine 2.5 mg/dL > 2.26 mg/dL): 1 point
S (prior stroke): 1 point
E (age 72 > 65 years): 1 point
D (NSAID use): 1 point

Total HAS-BLED Score: 5 — Very high risk (estimated annual major bleeding ~12.5%). Priority actions include tightening blood pressure control, discontinuing the NSAID if possible, and reassessing renal function regularly.

Limitations

The HAS-BLED score was originally validated in warfarin-treated patients; its calibration may differ slightly for those receiving direct oral anticoagulants (DOACs). As noted in the CUNY School of Public Health comparative analysis of HAS-BLED, ORBIT, and ATRIA scores, no single prediction tool perfectly captures every patient's individual bleeding profile, and clinical judgment remains indispensable alongside any calculated score.

Reference

Frequently asked questions

What is a high HAS-BLED score and what does it mean for treatment?

A HAS-BLED score of 3 or greater is classified as high bleeding risk, corresponding to an estimated annual major bleeding rate of approximately 3.7% or higher. Scores of 0–1 indicate low risk (around 1.0–1.1% per year) and a score of 2 indicates moderate risk (roughly 1.9% per year). A high score does not automatically contraindicate anticoagulation; instead it directs clinicians to identify and correct modifiable risk factors such as uncontrolled blood pressure, NSAID use, and excessive alcohol intake before or during therapy.

Does a high HAS-BLED score mean anticoagulation therapy should be stopped?

Not automatically. European Society of Cardiology guidelines explicitly state that a HAS-BLED score of 3 or more should prompt correction of reversible bleeding risks rather than serve as a standalone reason to withhold anticoagulation in atrial fibrillation patients. Because stroke risk in AF typically outweighs bleeding risk when CHA₂DS₂-VASc scores are 2 or higher, clinicians must weigh both scores together and address factors like uncontrolled hypertension, concurrent NSAID use, labile INR, and heavy alcohol consumption before making therapy decisions.

What does the letter A in HAS-BLED stand for, and how many points can it contribute?

The letter A stands for Abnormal renal or liver function, and it can contribute up to 2 points — one for each type of organ dysfunction assessed independently. Renal dysfunction is defined as dialysis dependence, kidney transplant, or serum creatinine above 2.26 mg/dL (200 µmol/L), scoring 1 point. Liver dysfunction — including cirrhosis, bilirubin more than twice the upper limit of normal, or transaminases more than three times normal — scores an additional separate point, meaning a patient with both conditions scores 2 points on this component alone.

How does a labile INR affect the HAS-BLED score and patient management?

Labile INR, the L component, adds 1 point when a patient on warfarin has an unstable international normalized ratio or a time in therapeutic range (TTR) below 60%. Poor INR control simultaneously elevates both bleeding and thromboembolic risk, making it one of the most consequential modifiable HAS-BLED factors. Clinicians may consider switching eligible patients to a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban, since DOACs maintain more predictable anticoagulation without routine INR monitoring and can effectively eliminate this risk factor from the score.

Is the HAS-BLED calculator validated for patients on direct oral anticoagulants (DOACs)?

The HAS-BLED score was originally developed and validated using data from patients receiving vitamin K antagonists such as warfarin, drawn from the Euro Heart Survey. While the score is widely applied to DOAC-treated patients in contemporary clinical practice, comparative analyses — including the CUNY School of Public Health review of HAS-BLED, ORBIT, and ATRIA — indicate that predictive accuracy may differ slightly across anticoagulant classes. Clinicians should apply HAS-BLED to DOAC patients with awareness of this limitation and may consider supplementary risk tools such as ORBIT or ATRIA for additional perspective.

How is the HAS-BLED score used alongside the CHA2DS2-VASc score?

HAS-BLED quantifies annual major bleeding risk while CHA₂DS₂-VASc estimates annual ischemic stroke risk in atrial fibrillation. Both scores are used together to determine net clinical benefit: when stroke risk substantially exceeds bleeding risk, anticoagulation is generally indicated. For example, a patient with a CHA₂DS₂-VASc score of 4 (high stroke risk) and a HAS-BLED score of 2 (moderate bleeding risk) typically benefits from anticoagulation, especially after modifiable bleeding factors are addressed. ESC guidelines recommend this dual-score approach as the standard framework for AF anticoagulation decision-making.